Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP7 | Q93009 | 12/20 | 0.83 |
| ▸ | JAK3 | P52333 | 1/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 6/20 | 0.36 |
| ▸ | PDCD1 | Q15116 | 6/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 6/20 | 0.36 |
| ▸ | CIT | O14578 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23911084 | 1.00 | USP7 (0.83) | USP7JAK3CHEK1PDCD1CD274 | |
| SCHEMBL23910803 | 1.00 | USP7 (0.83) | USP7JAK3CHEK1PDCD1CD274 | |
| SCHEMBL23910800 | 1.00 | USP7 (0.83) | USP7JAK3CHEK1PDCD1CD274 | |
| SCHEMBL23911006 | 1.00 | USP7 (0.83) | USP7JAK3CHEK1PDCD1CD274 | |
| SCHEMBL23911404 | 1.00 | USP7 (0.83) | USP7JAK3CHEK1PDCD1CD274 | |
| SCHEMBL23910814 | 1.00 | USP7 (0.83) | USP7JAK3CHEK1PDCD1CD274 | |
| SCHEMBL23911082 | 0.92 | USP7 (0.80) | USP7JAK3CIT | |
| SCHEMBL23911246 | 0.92 | USP7 (0.80) | USP7JAK3CIT | |
| SCHEMBL23921835 | 0.92 | USP7 (0.80) | USP7JAK3CIT | |
| SCHEMBL23910924 | 0.92 | USP7 (0.80) | USP7JAK3CIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317134-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | RAPT THERAPEUTICS INC (US) | 2021-10-14 | — | — | US | disclosed |
| US-20210317134-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | RAPT THERAPEUTICS INC (US) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317134-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | USP7, SENP7, USP8 | USP7 1/4885JAK3 3321/4885CHEK1 1102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.